Monoclonal Antibody Therapy

Atlantic General Hospital is now providing the monoclonal antibody therapy bamlanivimab for high risk patients with mild to moderate COVID-19 infections. The treatment, which comprises a single-dose, one-hour intravenous (IV) infusion, is not right for every individual who tests positive for COVID-19. Early research shows the therapy is most effective for those individuals with less severe symptoms who receive treatment early after symptoms first appear.

Notice to Providers
Referral Form

Due to limited supply, only those individuals at greatest risk of hospitalization will be eligible to receive the treatment. Referral for treatment is based upon specific criteria set by the Food and Drug Administration (FDA).

FDA Criteria for Treatment

• Have a body mass index (BMI) ≥35
• Have chronic kidney disease
• Have diabetes
• Have immunosuppressive disease
• Are currently receiving immunosuppressive treatment
• Are ≥65 years of age
• Are ≥55 years of age AND have
  • cardiovascular disease, or
  • hypertension, or
  • chronic obstructive pulmonary disease/other chronic respiratory disease.
• Are 12 – 17 years of age AND have
  • BMI ≥85th percentile for their age and gender based on CDC growth charts, or
  • sickle cell disease, or
  • congenital or acquired heart disease, or
  • neurodevelopmental disorders, for example, cerebral palsy, or
  • a medical-related technological dependence, for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19), or
  • asthma, reactive airway or other chronic respiratory disease that requires daily medication for control.

Receiving Treatment
Bamlanivimab infusion is provided through physician referral only, after it is determined that a patient is a good candidate for treatment.

Contact your primary care provider or visit our Atlantic ImmediCare clinic in Ocean City for testing and referral.